Correlation Between Cytogen and Bridge Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Cytogen and Bridge Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cytogen and Bridge Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cytogen and Bridge Biotherapeutics, you can compare the effects of market volatilities on Cytogen and Bridge Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cytogen with a short position of Bridge Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cytogen and Bridge Biotherapeutics.

Diversification Opportunities for Cytogen and Bridge Biotherapeutics

-0.55

Correlation Coefficient

Cytogen  Bridge Biotherapeutics

Excellent diversification

The 3 months correlation between Cytogen and Bridge is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Cytogen and Bridge Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bridge Biotherapeutics and Cytogen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cytogen are associated (or correlated) with Bridge Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bridge Biotherapeutics has no effect on the direction of Cytogen i.e., Cytogen and Bridge Biotherapeutics go up and down completely randomly.

Pair Corralation between Cytogen and Bridge Biotherapeutics

Assuming the 90 days trading horizon Cytogen is expected to under-perform the Bridge Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cytogen is 2.85 times less risky than Bridge Biotherapeutics. The stock trades about -0.11 of its potential returns per unit of risk. The Bridge Biotherapeutics is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest  375,000  in Bridge Biotherapeutics on December 29, 2024 and sell it today you would earn a total of  425,000  from holding Bridge Biotherapeutics or generate 113.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Cytogen  vs.  Bridge Biotherapeutics

Cytogen

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cytogen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Bridge Biotherapeutics

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Bridge Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bridge Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Cytogen and Bridge Biotherapeutics

The main advantage of trading using opposite Cytogen and Bridge Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cytogen position performs unexpectedly, Bridge Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will offset losses from the drop in Bridge Biotherapeutics' long position.

The idea behind Cytogen and Bridge Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.